Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Cancer Prev Res (Phila) ; 17(2): 51-57, 2024 02 02.
Article in English | MEDLINE | ID: mdl-38212272

ABSTRACT

Current lung cancer screening (LCS) guidelines rely on age and smoking history. Despite its benefit, only 5%-15% of eligible patients receive LCS. Personalized screening strategies select individuals based on their lung cancer risk and may increase LCS's effectiveness. We assess current LCS practices and the acceptability of personalized LCS among primary care providers (PCP) in Texas. We surveyed 32,983 Texas-based PCPs on an existing network (Protocol 2019-1257; PI: Dr. Shete) and 300 attendees of the 2022 Texas Academy of Family Physicians (TAFP) conference. We analyzed the responses by subgroups of interest. Using nonparametric bootstrap, we derived an enriched dataset to develop logistic regression models to understand current LCS practices and acceptability of personalized LCS. Response rates were 0.3% (n = 91) and 15% (n = 60) for the 2019-1257 and TAFP surveys, respectively. Most (84%) respondents regularly assess LCS in their practice. Half of the respondents were interested in adopting personalized LCS. The majority (66%) of respondents expressed concerns regarding time availability with the personalized LCS. Most respondents would use biomarkers as an adjunct to assess eligibility (58%), or to help guide indeterminate clinical findings (63%). There is a need to enhance the engagement of Texas-based PCPs in LCS. Most of the respondents expressed interest in personalized LCS. Time availability was the main concern related to personalized LCS. Findings from this project highlight the need for better education of Texas-based PCPs on the benefits of LCS, and the development of efficient decision tools to ensure successful implementation of personalized LCS. PREVENTION RELEVANCE: Personalized LCS facilitated by a risk model and/or a biomarker test is proposed as an alternative to existing programs. Acceptability of personalized approach among PCPs is unknown. The goal of this study is to assess the acceptability of personalized LCS among PCPs.


Subject(s)
Lung Neoplasms , Humans , Lung Neoplasms/diagnosis , Early Detection of Cancer/methods , Tomography, X-Ray Computed/methods , Texas , Primary Health Care , Mass Screening/methods
2.
Vaccines (Basel) ; 11(4)2023 Apr 20.
Article in English | MEDLINE | ID: mdl-37112784

ABSTRACT

The COVID-19 pandemic led to delays in routine preventative primary care and declines in HPV immunization rates. Providers and healthcare organizations needed to explore new ways to engage individuals to resume preventive care behaviors. Thus, we evaluated the effectiveness of using customized electronic reminders with provider recommendations for HPV vaccination to increase HPV vaccinations among adolescents and young adults, ages 9-25. Using stratified randomization, participants were divided into two groups: usual care (control) (N = 3703) and intervention (N = 3705). The control group received usual care including in-person provider recommendations, visual reminders in exam waiting rooms, bundling of vaccinations, and phone call reminders. The intervention group received usual care and an electronic reminder (SMS, email or patient portal message) at least once, and up to three times (spaced at an interval of 1 reminder per month). The intervention group had a 17% statistically significantly higher odds of uptake of additional HPV vaccinations than the usual care group (Adjusted Odds Ratio: 1.17, 95% CI: 1.01-1.36). This work supports previous findings that electronic reminders are effective at increasing immunizations and potentially decreasing healthcare costs for the treatment of HPV-related cancers.

3.
J Oncol Pract ; 15(12): 629-637, 2019 12.
Article in English | MEDLINE | ID: mdl-31825756

ABSTRACT

Chronic hepatitis C virus (HCV) infection increases the risk for several types of cancer, including hepatocellular carcinoma (HCC) and B-cell non-Hodgkin lymphoma, as primary and second primary malignancies. HCV-infected patients with cancer, particularly those undergoing anticancer therapy, are at risk for development of enhanced HCV replication, which can lead to hepatitis flare and progression of liver fibrosis or cirrhosis. Risk factors for HCV infection include injection drug use, blood transfusion, or solid organ transplantation before 1992, receipt of clotting factor concentrates before 1987, long-term hemodialysis, chronic liver disease, HIV positivity, and occupational exposure. Widely available direct-acting antivirals are highly effective against HCV and well tolerated. Identification of HCV-infected individuals is the essential first step in treatment and eradication of the infection. One-time screening is recommended for persons born from 1945 to 1965; screening is also recommended for persons with risk factors. Recently, a public health recommendation has been drafted to screen all adults age 18 to 79 years. Two oncology organizations recommend screening all patients with hematologic malignancies and hematopoietic cell transplant recipients, and a recently published multicenter prospective study supports universal HCV screening for all patients with cancer. HCV screening entails testing for anti-HCV antibodies in serum and, when results are positive, HCV RNA quantitation to confirm infection. Direct-acting antiviral therapy eradicates HCV in almost all cases. Virologic cure of HCV prevents chronic hepatitis and progression to liver fibrosis or cirrhosis. HCV eradication also decreases the risk of developing HCV-associated primary and second primary malignancies, and it may allow HCV-infected patients access to important cancer clinical trials. Patients with HCV-related cirrhosis require lifelong surveillance for HCC, even after viral eradication.


Subject(s)
Carcinoma, Hepatocellular/virology , Hepatitis C, Chronic/virology , Liver Neoplasms/virology , Lymphoma, Non-Hodgkin/virology , Adolescent , Adult , Aged , Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/pathology , Female , Hepacivirus/pathogenicity , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/epidemiology , Liver Cirrhosis/pathology , Liver Cirrhosis/virology , Liver Neoplasms/complications , Liver Neoplasms/epidemiology , Liver Neoplasms/pathology , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/epidemiology , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Risk Factors , Young Adult
4.
J Glob Oncol ; 4: 1-11, 2018 09.
Article in English | MEDLINE | ID: mdl-30241245

ABSTRACT

According to the Pan American Health Organization, noncommunicable diseases, including cancer, are the leading causes of preventable and premature death in the Americas. Governments and health care systems in Latin America face numerous challenges as a result of increasing morbidity and mortality from cancer. Multiple international organizations have recognized the need for collaborative action on and technical support for cancer research and control in Latin America. The Center for Global Health at the US National Cancer Institute (NCI-CGH) is one entity among many that are working in the region and has sought to develop a strategy for working in Latin America that draws on and expands the collaborative potential of engaged, skilled, and diverse partners. NCI-CGH has worked toward developing and implementing initiatives in collaboration with global partners that share the common objectives of building a global cancer research community and translating research results into evidence-informed policy and practice. Both objectives are complementary and synergistic and are additionally supported by an overarching strategic framework that is focused on partnerships and science diplomacy. This work highlights the overall strategy for NCI-CGH engagement in Latin America through partnerships and diplomacy, and highlights selected collaborative efforts that are aimed at improving cancer outcomes in the region.


Subject(s)
Diplomacy , International Cooperation , Neoplasms/epidemiology , Neoplasms/prevention & control , Research , Animals , Capital Financing , Global Health , Health Planning , Humans , Latin America/epidemiology , Public Health Surveillance , Research/economics , Research/legislation & jurisprudence , Research/organization & administration
5.
Am Soc Clin Oncol Educ Book ; 38: 262-279, 2018 May 23.
Article in English | MEDLINE | ID: mdl-30231359

ABSTRACT

The incidence rate of hepatocellular carcinoma (HCC) is rising. It is one of the most common cancers worldwide and accounts for substantial morbidity and mortality. Chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, and nonalcoholic fatty liver disease (NAFLD) are the most important etiologies of HCC, and effective screening and management strategies are crucial to reduce the HCC risk. For HBV, which accounts for the majority of HCC cases, most infections were acquired via perinatal and early horizontal transmission. Universal vaccination of newborns has led to a decline in HCC incidence compared with the pre-vaccination era. Effective antiviral therapies with nucleos(t)ide analogues or pegylated interferon reduced the incidence of HCC. For HCV, the emergence of effective direct-acting antiviral (DAA) agents has substantially improved cure rates; therefore all patients with HCV should be considered for DAA treatment. The most important obstacle in eliminating HCV is access to therapy. For NAFLD, the global incidence is increasing rapidly, thus its impact on HCC incidence may be explosive. Progression to HCC in NAFLD happens particularly in those with nonalcoholic steatohepatitis (NASH) and exacerbated by metabolic syndrome, or PNPLA3 gene polymorphism. Lifestyle changes are imperative while drug therapy has yet to demonstrate substantive protective effects on HCC prevention. For management of HCC, early diagnosis via imaging surveillance among persons with HCC risk factors remains the most important strategy to identify early-stage disease appropriate for resection or transplantation.


Subject(s)
Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/prevention & control , Liver Neoplasms/epidemiology , Liver Neoplasms/prevention & control , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/therapy , Disease Management , Global Health , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/therapy , Hepatitis B, Chronic/virology , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/therapy , Hepatitis C, Chronic/virology , Humans , Incidence , Liver Neoplasms/diagnosis , Liver Neoplasms/therapy , Non-alcoholic Fatty Liver Disease/complications , Non-alcoholic Fatty Liver Disease/diagnosis , Non-alcoholic Fatty Liver Disease/therapy , Population Surveillance
6.
J Clin Oncol ; 34(15): 1803-12, 2016 05 20.
Article in English | MEDLINE | ID: mdl-27069078

ABSTRACT

American Society of Clinical Oncology (ASCO), the leading medical professional oncology society, is committed to lessening the burden of cancer and as such will promote underused interventions that have the potential to save millions of lives through cancer prevention. As the main providers of cancer care worldwide, our patients, their families, and our communities look to us for guidance regarding all things cancer related, including cancer prevention. Through this statement and accompanying recommendations, ASCO hopes to increase awareness of the tremendous global impact of human papillomavirus (HPV) -caused cancers, refocus the discussion of HPV vaccination on its likely ability to prevent millions of cancer deaths, and increase HPV vaccination uptake via greater involvement of oncology professionals in ensuring accurate public discourse about HPV vaccination and calling for the implementation of concrete strategies to address barriers to vaccine access and acceptance.


Subject(s)
Papillomavirus Vaccines/immunology , Uterine Cervical Neoplasms/prevention & control , Vaccination , Female , Humans , Medical Oncology , Papillomavirus Vaccines/adverse effects , Physician's Role , Societies, Medical
7.
Prev Med Rep ; 2: 717-9, 2015.
Article in English | MEDLINE | ID: mdl-26844142

ABSTRACT

We examined the readiness of primary care clinicians to implement lung cancer screening programs in their practice settings in light of recent policy changes in the U.S. Attendees of two large continuing medical education events in Texas held in October and November of 2014 completed surveys about their current lung cancer screening practices and implementation needs. Surveys were completed by 350 participants (57.2% of registered attendees). Although 89.5% of participants routinely screened their patients for tobacco use, only 10.1% had a formal lung cancer screening program in their practice. More than half (56.0%) planned to refer eligible patients for lung cancer screening, 35.6% were not sure, and 8.3% did not plan to refer. Priority areas for implementing lung cancer screening programs in their settings included 1) greater clarity about coverage by private insurance and Medicare, 2) information about available screening centers offering low-dose computed tomography, 3) patient education and shared decision-making tools, 4) implementation toolkits and training for clinic staff, 5) integrating screening programs in electronic health records, and 6) more clarity about clinical guidelines. Practical needs related to identifying eligible patients, referral to screening centers, and tools for shared decision-making must be addressed before lung cancer screening can be implemented on a national scale.

8.
Tex Med ; 107(10): e1, 2011 Oct 01.
Article in English | MEDLINE | ID: mdl-21971841

ABSTRACT

The US Centers for Disease Control and Prevention releases annually an updated US Cancer Statistics report containing incidence and mortality data for all states and aggregate US data that allow for more meaningful comparisons across populations and geographic regions than do the number of new cases and deaths. This article examines major Texas findings from the most recent report (for the 5-year period 2003-2007) and compares Texas and United States.


Subject(s)
Neoplasms , Humans , Incidence , Texas/epidemiology , United States
9.
Tex Med ; 106(10): e1, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20890799

ABSTRACT

Previous studies have shown that a person's socioeconomic status (SES) (a proxy measure that can incorporate income, wealth, education, and occupation) is associated with cancer incidence and mortality. Examining variation in cancer rates by SES can help identify health disparities and target areas for cancer control activities. The Texas Cancer Registry (TCR) collects data on every newly diagnosed case of cancer in Texas, including personal and demographic data, but does not collect data related directly to SES. Using a county-level measure of SES determined by the 2000 US Census, we compared cancer incidence and mortality rates for selected cancer sites by counties categorized into Low, Intermediate, and High SES. The cancers examined in this analysis included lung, colorectal, female breast, prostate, cervical, and all cancers collected by TCR combined. Consistent with other studies, most incidence and mortality rates were lowest in the High SES counties. However, in general, the highest incidence and mortality rates were found in counties categorized as Intermediate SES, but patterns differed by cancer site and by race and ethnicity. This study provides additional evidence that geographically related SES is associated with cancer incidence and mortality.


Subject(s)
Neoplasms , Social Class , Humans , Incidence , Texas/epidemiology
10.
Fam Med ; 41(5): 332-6, 2009 May.
Article in English | MEDLINE | ID: mdl-19418281

ABSTRACT

BACKGROUND AND OBJECTIVES: Our objective was to describe and evaluate an educational intervention for teaching preclinical medical students enrolled in a family medicine preceptorship to use evidence-based medicine (EBM) techniques. METHODS: In a brief workshop, 94 preclinical students, enrolled in a 4?week family medicine preceptorship, learned an EBM approach to clinical decision making. Students were responsible for completing four patient case summaries to document that they had searched selected databases and obtained feedback from their preceptors. We then evaluated (1) the percent of students documenting EBM processes, (2) the students' perceived self-efficacy, (3) the level of the students' EBM learning, and (4) preceptors' attitudes toward using the EBM project as the focus of their feedback. RESULTS: All students succeeded in identifying the factual knowledge that they had used to convert information from patient encounters into searchable clinical questions. The preceptors provided case-specific, written feedback to all students. Students gave lesser ratings of importance to EBM and self-efficacy in using EBM after the preceptorship as compared to after the brief introductory workshop. Preceptors acknowledged that the project helped them to focus their feedback and to reconsider patient management practices. CONCLUSIONS: Students learned to use an EBM process and became more familiar with and more realistic about their self-efficacy in using EBM. Preceptors and preclinical medical students can learn and hone EBM skills together.


Subject(s)
Education, Medical, Undergraduate/methods , Evidence-Based Medicine/education , Family Practice/education , Preceptorship/methods , Attitude of Health Personnel , Educational Measurement , Humans , Patient Care/methods , Physicians, Family , Program Evaluation , Students, Medical , Surveys and Questionnaires
11.
Fam Med ; 37(2): 105-11, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15690250

ABSTRACT

BACKGROUND: Family medicine preceptorships are underused opportunities for learning smoking cessation counseling skills. To prepare students for their future roles in preventing health problems in patients who use tobacco, we implemented a patient-centered instructional module within the elective Texas Statewide Family Practice Preceptorship Program. METHODS: Seventy-eight preclinical medical students learned to screen for tobacco use and perform smoking cessation counseling using brief motivational methods. Students practiced these skills under the supervision of community preceptors. Program evaluation included measurement of the percentage of students who documented that they could screen for tobacco use, their increase in knowledge and sense of self efficacy in conducting smoking cessation counseling, and performance of appropriate and time-efficient interventions. RESULTS: Fifty-four of 78 students screened 1,891 patients and documented 593 current tobacco users. The students provided appropriate smoking cessation intervention for 539 (91%) of these patients. Each intervention session took approximately 5 to 10 minutes. There was a more than 50% increase in the proportion of students who "agreed" or "strongly agreed" to having increased their knowledge and confidence in conducting smoking cessation counseling between the orientation and the end of their summer preceptorship. CONCLUSIONS: With focused training, preclinical medical students can successfully learn and practice patient-centered screening and smoking cessation counseling skills in a community preceptorship setting that fits the needs of busy preceptors and prepares students for their future roles in tobacco control.


Subject(s)
Family Practice/education , Preceptorship , Smoking Cessation/methods , Chi-Square Distribution , Clinical Clerkship/methods , Counseling/methods , Female , Humans , Male , Middle Aged , Preceptorship/methods , Statistics, Nonparametric , Surveys and Questionnaires
12.
Acad Med ; 79(1): 62-8, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14690999

ABSTRACT

PURPOSE: Since 1979, the Texas Statewide Family Practice Preceptorship Program (TSFPPP) has conducted ambulatory preceptorships to increase the number of medical students selecting family practice residencies. The authors describe the evaluation of the TSFPPP's efficacy in terms of four evaluation questions and outcome measures identified by program users from eight Texas medical schools. METHOD: The authors compared the proportion of 10,081 Texas medical school students graduating from 1992-2000 who chose family practice or other primary care residencies following participation or nonparticipation in the TSFPPP's preclinical and clinical programs. RESULTS: The proportion of students choosing family practice residencies among TSFPPP participants was significantly greater than among nonparticipants. Participation in the TSFPPP was associated with an increased choice of a family practice residency for students who were involved in the TSFPPP at the preclinical level (odds ratio [OR], 1.62; 95% confidence interval [CI], 1.41-1.87); the clinical level (OR, 2.31; 95% CI, 1.99-2.68); and both levels (OR, 4.98; 95% CI, 3.75-6.68) compared to non-TSFPPP participation. There was a 44% increase in preceptors willing to teach medical students. CONCLUSIONS: Participation in the TSFPPP is associated with a greater likelihood of students selecting a family practice residency. The interinstitutional approach to analyzing effects of the preceptorship on students' specialty choices focuses attention on primary care issues that, in the long run, may affect an entire state's health care delivery system.


Subject(s)
Career Choice , Family Practice/education , Internship and Residency , Preceptorship , Adult , Female , Humans , Male , Primary Health Care , Program Evaluation , Texas
SELECTION OF CITATIONS
SEARCH DETAIL
...